Exodus Point Capital Management, LP Cure Vac N.V. Transaction History

Exodus Point Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$2.31 - $4.99 $533,166 - $1.15 Million	-230,808 Reduced 90.45%	24,356 $83,000
Q1 2024 May 14, 2024	BUY	$2.94 - $4.34 $750,182 - $1.11 Million	255,164 New	255,164 $773,000
Q3 2022 Nov 10, 2022	SELL	$7.48 - $15.24 $89,722 - $182,803	-11,995 Closed	0 $0
Q2 2022 Aug 19, 2022	SELL	$13.18 - $19.41 $261,082 - $384,492	-19,809 Reduced 62.28%	11,995 $163,000
Q1 2022 May 13, 2022	BUY	$14.73 - $35.25 $468,472 - $1.12 Million	31,804 New	31,804 $624,000
Q4 2021 Feb 11, 2022	SELL	$33.72 - $48.22 $854,734 - $1.22 Million	-25,348 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$49.26 - $74.5 $1.25 Million - $1.89 Million	25,348 New	25,348 $1.39 Million
Q2 2021 Aug 16, 2021	SELL	$56.91 - $127.53 $142,047 - $318,314	-2,496 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$79.79 - $126.29 $155,271 - $245,760	1,946 Added 353.82%	2,496 $228,000
Q4 2020 Feb 16, 2021	BUY	$46.76 - $136.27 $25,718 - $74,948	550 New	550 $45,000

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.